iRadimed (IRMD) to Release Earnings on Thursday

iRadimed (NASDAQ:IRMD) is anticipated to announce its Q4 2025 results before the market opens on Thursday, February 12th. Analysts expect iRadimed to post earnings of $0.49 per share and revenue of $21.5970 million for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, February 10, 2026 at 11:00 AM ET.

iRadimed (NASDAQ:IRMD) last released its earnings results on Monday, November 3rd. The medical equipment provider reported $0.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.43 by $0.04. iRadimed had a return on equity of 22.93% and a net margin of 26.31%.The firm had revenue of $21.20 million during the quarter, compared to analyst estimates of $20.50 million. On average, analysts expect iRadimed to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

iRadimed Price Performance

Shares of NASDAQ IRMD opened at $93.85 on Thursday. The company has a market cap of $1.19 billion, a price-to-earnings ratio of 56.88 and a beta of 1.11. The stock’s 50-day moving average is $97.65 and its two-hundred day moving average is $82.09. iRadimed has a 1-year low of $47.48 and a 1-year high of $104.93.

iRadimed Dividend Announcement

The company also recently announced a special dividend, which was paid on Tuesday, December 30th. Investors of record on Wednesday, December 17th were paid a dividend of $0.50 per share. The ex-dividend date was Wednesday, December 17th. iRadimed’s dividend payout ratio is presently 41.21%.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on IRMD. Roth Mkm set a $90.00 target price on shares of iRadimed in a report on Friday, October 31st. Zacks Research upgraded shares of iRadimed to a “hold” rating in a report on Tuesday, November 4th. Lake Street Capital reaffirmed a “buy” rating and set a $100.00 price objective on shares of iRadimed in a research report on Monday, November 3rd. Wall Street Zen lowered iRadimed from a “strong-buy” rating to a “buy” rating in a report on Sunday, October 26th. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of iRadimed in a research note on Monday, December 29th. Three analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, iRadimed has an average rating of “Moderate Buy” and a consensus price target of $95.00.

Insider Buying and Selling at iRadimed

In related news, CFO John Glenn sold 15,000 shares of the stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $97.29, for a total value of $1,459,350.00. Following the transaction, the chief financial officer directly owned 7,362 shares of the company’s stock, valued at $716,248.98. This trade represents a 67.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Roger E. Susi sold 5,000 shares of the business’s stock in a transaction on Monday, January 26th. The shares were sold at an average price of $100.65, for a total transaction of $503,250.00. Following the completion of the sale, the chief executive officer directly owned 2,262,500 shares of the company’s stock, valued at approximately $227,720,625. This trade represents a 0.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 55,000 shares of company stock valued at $5,287,900. Company insiders own 36.80% of the company’s stock.

Institutional Trading of iRadimed

A number of large investors have recently made changes to their positions in IRMD. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of iRadimed by 5.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider’s stock valued at $252,000 after purchasing an additional 234 shares during the period. Tower Research Capital LLC TRC lifted its position in shares of iRadimed by 191.1% during the 2nd quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after acquiring an additional 495 shares during the period. Quarry LP purchased a new stake in shares of iRadimed during the 3rd quarter worth approximately $40,000. Qube Research & Technologies Ltd grew its holdings in shares of iRadimed by 2.0% in the 2nd quarter. Qube Research & Technologies Ltd now owns 48,537 shares of the medical equipment provider’s stock worth $2,902,000 after acquiring an additional 964 shares during the period. Finally, AQR Capital Management LLC increased its stake in iRadimed by 7.5% in the 1st quarter. AQR Capital Management LLC now owns 15,829 shares of the medical equipment provider’s stock valued at $831,000 after purchasing an additional 1,108 shares in the last quarter. 92.34% of the stock is owned by institutional investors and hedge funds.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.